Cargando…

Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy

OBJECTIVE: Nomograms are statistics-based predictive tools that integrate predictive factors. Herein, a nomogram was developed and validated to predict the overall survival (OS) in serous ovarian cancer (SOC). METHODS: Primary SOC patients with satisfactory cytoreductive surgery, chemotherapy, and O...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuan-Yuan, Zhao, Ren-Feng, Liu, Chao, Zhou, Jie, Yang, Liu, Li, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747526/
https://www.ncbi.nlm.nih.gov/pubmed/35023951
http://dx.doi.org/10.2147/IJGM.S337827
_version_ 1784630854661701632
author Liu, Yuan-Yuan
Zhao, Ren-Feng
Liu, Chao
Zhou, Jie
Yang, Liu
Li, Li
author_facet Liu, Yuan-Yuan
Zhao, Ren-Feng
Liu, Chao
Zhou, Jie
Yang, Liu
Li, Li
author_sort Liu, Yuan-Yuan
collection PubMed
description OBJECTIVE: Nomograms are statistics-based predictive tools that integrate predictive factors. Herein, a nomogram was developed and validated to predict the overall survival (OS) in serous ovarian cancer (SOC). METHODS: Primary SOC patients with satisfactory cytoreductive surgery, chemotherapy, and OS ≥1 month were included in this study. A total of 6957 patients from the Surveillance, Epidemiology, and End Results (SEER) database comprised the training group and 1244 patients comprised the external validation group. The nomogram was structured on Cox models and evaluated in both the training and validation groups using consistency index, area under the receiver operating characteristics curve, calibration plots, and risk subgroup classification. Kaplan–Meier curves were plotted to compare the survival outcomes between subgroups. A decision-curve analysis was used to test the clinical value of the nomogram. RESULTS: Independent factors, including age, tumor grade, and Federation of Gynecology and Obstetrics (FIGO) stage, identified by multivariate analysis in the training cohort, were selected for the nomogram. The consistency indexes for OS were 0.689 in the training cohort and 0.639 in the validation cohort. The calibration curves showed good consistency between predicted and actual 3- and 5-year OS. Significant differences were observed in the survival curves of different risk subgroups. The decision-curve analysis indicated that our nomogram was superior to the American Joint Committee on Cancer (AJCC) staging system. CONCLUSION: A nomogram was constructed to predict the long-term OS in SOC and verified in Asians. The accurate predictions facilitated personalized treatments and follow-up strategies.
format Online
Article
Text
id pubmed-8747526
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-87475262022-01-11 Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy Liu, Yuan-Yuan Zhao, Ren-Feng Liu, Chao Zhou, Jie Yang, Liu Li, Li Int J Gen Med Original Research OBJECTIVE: Nomograms are statistics-based predictive tools that integrate predictive factors. Herein, a nomogram was developed and validated to predict the overall survival (OS) in serous ovarian cancer (SOC). METHODS: Primary SOC patients with satisfactory cytoreductive surgery, chemotherapy, and OS ≥1 month were included in this study. A total of 6957 patients from the Surveillance, Epidemiology, and End Results (SEER) database comprised the training group and 1244 patients comprised the external validation group. The nomogram was structured on Cox models and evaluated in both the training and validation groups using consistency index, area under the receiver operating characteristics curve, calibration plots, and risk subgroup classification. Kaplan–Meier curves were plotted to compare the survival outcomes between subgroups. A decision-curve analysis was used to test the clinical value of the nomogram. RESULTS: Independent factors, including age, tumor grade, and Federation of Gynecology and Obstetrics (FIGO) stage, identified by multivariate analysis in the training cohort, were selected for the nomogram. The consistency indexes for OS were 0.689 in the training cohort and 0.639 in the validation cohort. The calibration curves showed good consistency between predicted and actual 3- and 5-year OS. Significant differences were observed in the survival curves of different risk subgroups. The decision-curve analysis indicated that our nomogram was superior to the American Joint Committee on Cancer (AJCC) staging system. CONCLUSION: A nomogram was constructed to predict the long-term OS in SOC and verified in Asians. The accurate predictions facilitated personalized treatments and follow-up strategies. Dove 2022-01-06 /pmc/articles/PMC8747526/ /pubmed/35023951 http://dx.doi.org/10.2147/IJGM.S337827 Text en © 2022 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liu, Yuan-Yuan
Zhao, Ren-Feng
Liu, Chao
Zhou, Jie
Yang, Liu
Li, Li
Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy
title Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy
title_full Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy
title_fullStr Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy
title_full_unstemmed Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy
title_short Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy
title_sort development and validation of nomograms to predict overall survival outcomes in serous ovarian cancer patients with satisfactory cytoreductive surgery and chemotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747526/
https://www.ncbi.nlm.nih.gov/pubmed/35023951
http://dx.doi.org/10.2147/IJGM.S337827
work_keys_str_mv AT liuyuanyuan developmentandvalidationofnomogramstopredictoverallsurvivaloutcomesinserousovariancancerpatientswithsatisfactorycytoreductivesurgeryandchemotherapy
AT zhaorenfeng developmentandvalidationofnomogramstopredictoverallsurvivaloutcomesinserousovariancancerpatientswithsatisfactorycytoreductivesurgeryandchemotherapy
AT liuchao developmentandvalidationofnomogramstopredictoverallsurvivaloutcomesinserousovariancancerpatientswithsatisfactorycytoreductivesurgeryandchemotherapy
AT zhoujie developmentandvalidationofnomogramstopredictoverallsurvivaloutcomesinserousovariancancerpatientswithsatisfactorycytoreductivesurgeryandchemotherapy
AT yangliu developmentandvalidationofnomogramstopredictoverallsurvivaloutcomesinserousovariancancerpatientswithsatisfactorycytoreductivesurgeryandchemotherapy
AT lili developmentandvalidationofnomogramstopredictoverallsurvivaloutcomesinserousovariancancerpatientswithsatisfactorycytoreductivesurgeryandchemotherapy